1.
ASCO Speaker - Valérie Quadvlieg - ASCO
The American Society of Clinical Oncology (ASCO) is the world's leading professional organization representing physicians who treat people with cancer.
2.
Epidemiologic characteristics of colon cancer in Asian Indian and ...
Colon cancer is the second most common in male and third most common cancer in females in Asian Indian and Pakistani population living in the USA. ...
3.
Cost comparison and cost efficacy analysis between fludarabine (F ...
Cost comparison and cost efficacy analysis between fludarabine (F) and cyclophosphamide vincristine and prednisone (CVP) treatments for low-grade non ...
4.
ASCO Speaker - Theodore S. Lawrence - ASCO
... in patients with non-small cell lung cancer: A combined analysis from Beijing and Michigan. ... Virtual Meeting Presentations by Theodore S. Lawrence ...
5.
Alternate CAV/IE combination chemotherapy in advanced soft-tissue ...
Materials and Methods:We used alternate VAC/IE chemotherapy regimen to treat locally advanced and metastatic round cell tumors. ...
6.
Epidermal growth factor receptor immunohistochemistry (EGFR IHC ...
Epidermal growth factor receptor immunohistochemistry (EGFR IHC): assay ... The recently developed DAKO EGFR pharmDx IHC assay (mAb 218C9) was fairly ...
7.
Death predicictive factor in terminal cancer patients. - ASCO
Methods: We enrolled 121 patients with the terminal cancer of Kangnam St. Mary's Hospital from September 2004 until their death. We observed symptoms shown ...
8.
Alternate CAV/IE combination chemotherapy in advanced soft-tissue ...
The CAV regimen (phase-I) consisted of cyclophosphamide (CTX) 1200 mg/m2 IV 1 hour infusion day-1, adriamycin 75 mg/m2 IV 24 hour continuous infusion day-1, ...
9.
FIRST LINE EPIRUBICIN (EPI) AND TAXOTERE (TXT) IN ADVANCED BREAST ...
A multicenter phase II study of trastuzumab with epirubicin and docetaxel as a first line treatment in metastatic breast cancer. ...
10.
Phase III trial of iseganan HCl oral solution (iseganan) for ...
Iseganan, also known as IB-367, disrupts microbial membrane integrity ... In the reported Phase 3 trial (n=323), iseganan prevented ulcerative OM (P=0.067). ...